Log in
E-mail
Password
Remember
Forgot password ?
Become a member for free
Sign up
Sign up
Settings
Settings
Dynamic quotes 
OFFON

4-Traders Homepage  >  Equities  >  Nyse  >  CVS Health    CVS

CVS HEALTH (CVS)
Mes dernières consult.
Most popular
Report
SummaryQuotesChartsNewsAnalysisCalendarCompanyFinancialsConsensusRevisions 
News SummaryMost relevantAll newsSector newsTweets

CVS Caremark 4th-Quarter Profit Rose 2.6% Amid Continued Sales Growth

share with twitter share with LinkedIn share with facebook
share via e-mail
0
02/06/2013 | 01:52pm CET
   By Tess Stynes 
 

CVS Caremark Corp.'s (>> CVS Caremark Corporation) fourth-quarter earnings rose 2.6% as the company reported revenue growth in its pharmacy-services and retail drugstore operations.

For the year, the company raised its forecast for per-share adjusted earnings from continuing operations by two cents and now expects $3.86 to $4.

CVS's retail pharmacy business gained customers last year in the wake of a contract dispute between rival Walgreen Co.'s (>> Walgreen Company) and pharmacy-benefits manager Express Scripts Holding Co. (>> Express Scripts Holding Co) that has since been resolved.

A wave of major generic drugs introductions is having a mixed effect on the industry. Though the copycat drugs carry higher margins than branded products, they command lower prices, hurting sales revenue.

CVS Caremark reported a profit of $1.13 billion, or 90 cents a share, up from $1.1 billion, or 81 cents a share, a year earlier. Excluding debt-extinguishment losses, acquisition-related charges and other items, adjusted earnings from continuing operations were $1.14. Revenue increased 11% to $31.39 billion.

Analysts polled by Thomson Reuters most recently projected earnings of $1.10 on revenue of $31.13 billion.

Revenue in the larger pharmacy-services business climbed 17% to $18.6 billion, reflecting new client starts, higher prices and growth of its Medicare Part D program. Pharmacy network claims processed rose 6.5%.

On the retail side, revenue increased 5.1% to $16.3 billion. Same-store sales were up 4% from a year earlier, as pharmacy same-store sales also improved by 4%. Same-store sales in the front end of the store grew 3.9%.

Shares closed Tuesday at $51.72 and were inactive premarket.

Write to Tess Stynes at [email protected]

Subscribe to WSJ: http://online.wsj.com?mod=djnwires

share with twitter share with LinkedIn share with facebook
share via e-mail
0
Latest news on CVS HEALTH
01/19 Delaware sues opioid manufacturers, distributors over epidemic
01/19 CVS HEALTH : FORTUNE Recognizes CVS Health on 2018 List of "World's Most Admired..
01/19 CVS HEALTH : FORTUNE® Recognizes CVS Health on 2018 List of "World's Most Admire..
01/18 AETNA : Shareholder Sues To Block CVS Deal
01/17 CVS HEALTH : Launches New Transform Rheumatoid Arthritis Care Program to Improve..
01/17 CVS HEALTH : Launches New Transform Rheumatoid Arthritis Care™ Program to ..
01/16 CVS ADDS 42 DRUG DISPOSAL BOXES ACRO : Here's where you can drop off unwanted me..
01/16 CVS HEALTH : opening drug disposal units in 40 locations, including 2 in Greater..
01/16 CVS HEALTH : to stop touchups in ads
01/15 CVS HEALTH : says it will no longer touch up photos used in marketing of beauty ..
More news
News from SeekingAlpha
01/18 CVS Health Reminds Us That Investing Is 90% Half Common Sense
01/18 BY THE NUMBERS : Hunting For Undervalued Stocks
01/18 11 Upcoming Dividends Including 2 Kings
01/18 10 Dividend Growth Stocks For January 2018
01/18 The Best Way To Aim At The Target For The Next 12 Months
Financials ($)
Sales 2017 184 B
EBIT 2017 9 944 M
Net income 2017 5 216 M
Debt 2017 24 376 M
Yield 2017 2,49%
P/E ratio 2017 15,94
P/E ratio 2018 14,13
EV / Sales 2017 0,57x
EV / Sales 2018 0,54x
Capitalization 80 898 M
Chart CVS HEALTH
Duration : Period :
CVS Health Technical Analysis Chart | CVS | US1266501006 | 4-Traders
Technical analysis trends CVS HEALTH
Short TermMid-TermLong Term
TrendsBullishNeutralNeutral
Income Statement Evolution
Consensus
Sell
Buy
Mean consensus OUTPERFORM
Number of Analysts 23
Average target price 88,0 $
Spread / Average Target 10%
EPS Revisions
Managers
NameTitle
Larry J. Merlo President, CEO & Non-Independent Director
David Wyatt Dorman Chairman
Jonathan C. Roberts Chief Operating Officer & Executive Vice President
David M. Denton Chief Financial Officer & Executive Vice President
Troyen A. Brennan Chief Medical Officer & Executive Vice President
Sector and Competitors
1st jan.Capitalization (M$)
CVS HEALTH9.66%80 898
WALGREENS BOOTS ALLIANCE4.35%75 733
EXPRESS SCRIPTS HOLDING CO7.18%45 434
MCKESSON CORPORATION10.82%35 516
CARDINAL HEALTH18.57%22 667
AMERISOURCEBERGEN10.32%21 821